NCT00918775Active, not recruitingPhase 2
Follow-up After Metastasectomy in Patients With Kidney Cancer
A Phase II Metastasectomy Study for Patients With Renal Cell Carcinoma
Source: ClinicalTrials.gov · Last updated 6 Oct 2026
Brief summary (registry, in English)
This phase II trial studies the follow-up after metastasectomy in patients with kidney cancer. Following up patients' health condition after metastasectomy may help doctors to learn if the surgical removal of the primary tumor or the parts of the cancer that has spread to other parts of the body is a good method for treating patients who have kidney cancer.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 86 (actual)
- First submitted
- 10 Jun 2009
- Start date
- Jun 2009
- Primary completion date
- Dec 2026
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Kidney cancer, Childhood cancers
- NCT number
- NCT00918775
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 86
- From Jun 2009 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients must not have active acute infections that could be worsened by surgery or interfere with this study
- Patients must not have clinically significant cardiovascular disease, or peripheral vascular disease that creates an unacceptably high operative risk
- Patients must not have a history of uncontrolled severe depression
Lab values
- Patients must not have history of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates surgical resection, or render the subject at high risk from treatment complications
Who the study is looking for
- Patients with histologically or cytologically confirmed renal cell carcinoma (RCC)
- Patients have clinical reasons for undergoing a surgical resection of tumor; there are two main categories of patients:
- Patients with fully resectable disease as defined by lesions accessible by a surgeon during no more than two separate surgical sessions, and are expected to be rendered surgically no evidence of disease (NED)
- Patients undergoing a noncurative procedure for relief of symptoms or for management of threatening lesions
- Patients have been deemed resectable by the subspecialty surgeon involved in the patient's care
- Patients must give written informed consent prior to initiation of therapy, in keeping with the policies of the institution; patients with a history of major psychiatric illness must be judged able to fully understand the investigational nature of the study and the risks associated with the therapy; the only approved consent is attached to this protocol
- Patients must have ability to comply with study and/or follow-up procedures
- Members of all races and ethnic groups are eligible for this trial
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| M D Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.